You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: RIP ROAD, INC.            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. An Interactive Education Program to Reduce High Risk Behavior in Adolescents

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A Disease-Modifying Protein Therapeutic for the Treatment of COPD

    SBC: VERRA THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms

    SBC: NEUROVASCULAR DIAGNOSTICS, INC.            Topic: 103

    Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Non-Clinical Pharmacology of CX-01

    SBC: Ceramedix Holding, LLC            Topic: NIAID

    Development of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as radiological dispersal devices (i.e., “dirty bomb”) and nuclear accidents, which may be caused by extreme weather (such as occurred in Fukushima, Japan in 2011). Radiation exposure can be potentially lethal via the hematopoietic-acute radiation syndrome (H-ARS) and the gastro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating

    SBC: Halomine Inc.            Topic: NIAID

    Project Summary/Abstract In the US, about 1.7 million Healthcare-Associated Infections (HAls) occur in hospitals each year, resulting in 99,000 deaths and an estimated $20 billion in healthcare costs. According to previous reports, as much as one third of HAI cases can be attributed to environmental surfaces, namely “high touch” surfaces (e.g., bed rails, machine buttons, equipment), in hospit ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a novel EEG-based index for evaluating amyloid and tau burden in Alzheimer's Disease

    SBC: Spark Neuro Inc.            Topic: NIA

    PROJECT SUMMARY Alzheimer’s disease (AD) is a progressive, neurodegenerative condition that impacts 44 million people globally. It is the most common cause of dementia—accounting for 80% of all dementia diagnoses—and predominantly affects older people. To date, AD has no cure. Thus, it is imperative to diagnose patients as early as possible to maximize the efficacy of symptom management stra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government